Summary:
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and pharmacokinetics of SAGE-547 injection in the treatment of adult female subjects with severe postpartum depression and adult female subjects with moderate postpartum depression
Qualified Participants Must:
• Be female aged between 18 and 45 years of age
• Subject has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery
• Subject is 6 months postpartum
•
Subject must use one of the study approved methods of birth control during participation in the study and for 30 days following the end of the study drug
Qualified Participants May Receive:
Compensation for time and travel